Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02015520 · ClinicalTrials.gov registry record · Phase 2
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT02015520 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 143 participants.
The verdict
NCT02015520, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
The primary purpose of this study is to identify an appropriate dose of study medication.
Interventions
- DRUG Clazakizumab
- DRUG Placebo (Matching with Clazakizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02015520
The ClinicalTrials.gov registry entry for NCT02015520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clazakizumab is the first listed.
NCT02015520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02015520 about?
NCT02015520 is a clinical study titled "Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis". The primary purpose of this study is to identify an appropriate dose of study medication.
What is the current status of trial NCT02015520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2012-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02015520?
The interventions under investigation include: Clazakizumab (DRUG), Placebo (Matching with Clazakizumab) (DRUG).
Who is sponsoring clinical trial NCT02015520?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.